Compare Merck & Co., Inc. (MRK) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Merck & Co., Inc. trades at $141.98 (market cap $351.28B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.22 (market cap $323.80B). The key difference: Merck & Co., Inc. and Vanguard Tax Managed Fund FTSE Developed Markets ETF are close in size by market cap, and Merck & Co., Inc. pays a 2.39% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| MRK | VEA | |
|---|---|---|
Market Cap | $351.28B | $323.80B |
Volume | 7,969,665 | 17,001,112 |
Sector | Health | — |
52-Week High | $156.43 | $73.79 |
52-Week Low | $82.49 | $58.90 |
Typical Hold Time | 98 Days | 131 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Vanguard FTSE Developed Markets ETF (VEA) trades at $70.26, down 1.2% today, with a bearish technical signal from moving averages. The ETF offers exposure to developed markets outside the U.S. with a low 0.03% expense ratio and a recent dividend declared for September 2026. Recent news highlights its cost advantage over peers and mixed institutional activity, with some firms increasing stakes while others reduced positions.
VEA provides diversified international exposure at minimal cost, but near-term technical weakness and reliance on global economic stability pose risks. The fund's appeal lies in its efficiency and yield, yet investors face currency and geopolitical uncertainties inherent in non-U.S. markets. Long-term prospects depend on sustained growth in developed economies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
